Abstract 2208: Clinicopathological and genetic study of ovarian cancer in Algerian women: First report
Authors: Cherbal Farid , Mehemmai Chiraz , Boumehdi Lamia , Khider Feriel , Boucheffa Amina , Gaceb Hadjer , Mahfouf Hassen , Bakour Rabah 
Published: August 2018

Background: Ovarian cancer represents the fourth most common cause of mortality among Algerian women. Of all gynecological malignancies, ovarian cancer causes the highest number of deaths in women in Algeria. In the present study, we sought to determine for the first time, clinical, tumor and genetic characteristics associated with ovarian cancer in Algerian women. We also screened for specific mutations in BRCA1 and BRCA2 genes in patients with positive family history of ovarian cancer.

Materials and Methods: The study population included 244 patients diagnosed with ovarian cancer. Ovarian carcinomas were diagnosed between 2011 and 2016. Data were collected from cancer registries of public hospitals that covered 10 provinces of Algeria. Patient and tumor information included: age at diagnosis, histological type, histological grade, TNM stage, preoperative tumors markers CEA and CA-125 serum levels, family history with ovarian cancer or any cancer, age at menarche, oral contraception and breast feeding. BRCA1 exon 11 and BRCA2 exon 22 were screened by PCR-direct sequencing in 11 patients with a family history of ovarian cancer for two common mutations that were previously found in Algerian population, respectively.

Results: The median age at diagnosis cancer was 51.02 years. The mean age at menarche was 13.04 years. We noticed that 43.85 % of women have been diagnosed with ovarian cancer at younger age (&lt; 50 years). The proportion of ovarian cancer patients with premenopausal status was 39.75%. The commonest histological subtypes was serous adenocarcinoma (52.45%) followed by endometrioid (10.65%), mucinous (9.43%) and clear cell carcinoma (4.09%). We found that the proportion of tumors with histological grade II (41.8%) and grade III (27.86%) was commonest in 70% of the patients. Our results showed that 61.46% of the patients were diagnosed at stage II (39.34%), stage III (8.6%) and stage IV (13.52%), respectively. 73.36% and 18.08% of the patients were positive for CA-125 and CEA, respectively. We noticed that 29 patients (11.88%) had a positive family history of ovarian cancer. 141 patients (57.78%) had breastfed and 107 patients (43.85%) were using contraception.The BRCA1 mutation c.2125_2126insA and BRCA2 mutation c.8940delA have not been detected in our patients.

Conclusions: For the first time, we report here some clinical, biological, tumor and genetic characteristics of ovarian cancer in Algerian women. Our study showed that ovarian cancer in Algerian women has some similar clinicopathological and biological features with women of European descent. Interestingly, the median age of diagnosis in ovarian cancer patients was younger than average age in Europe and America. High frequency of patients with positive family history of ovarian cancer could be linked to genetic background of Algerian population. Further studies are needed to reaffirm our findings. BRCA1 and BRCA2 analysis are ongoing in our patients.

Citation Format: Farid Cherbal, Chiraz Mehemmai, Lamia Boumehdi, Feriel Khider, Amina Boucheffa, Hadjer Gaceb, Hassen Mahfouf, Rabah Bakour. Clinicopathological and genetic study of ovarian cancer in Algerian women: First report [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2208.